296 related articles for article (PubMed ID: 19200217)
1. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection.
Rocha PN; Butterly DW; Greenberg A; Reddan DN; Tuttle-Newhall J; Collins BH; Kuo PC; Reinsmoen N; Fields T; Howell DN; Smith SR
Transplantation; 2003 May; 75(9):1490-5. PubMed ID: 12792502
[TBL] [Abstract][Full Text] [Related]
4. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
5. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.
Lehrich RW; Rocha PN; Reinsmoen N; Greenberg A; Butterly DW; Howell DN; Smith SR
Hum Immunol; 2005 Apr; 66(4):350-8. PubMed ID: 15866697
[TBL] [Abstract][Full Text] [Related]
8. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
[TBL] [Abstract][Full Text] [Related]
9. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
[TBL] [Abstract][Full Text] [Related]
11. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
13. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.
Mulley WR; Hudson FJ; Tait BD; Skene AM; Dowling JP; Kerr PG; Kanellis J
Transplantation; 2009 Jan; 87(2):286-9. PubMed ID: 19155986
[TBL] [Abstract][Full Text] [Related]
14. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation.
Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Harada N; Iguchi T; Hashimoto N; Maehara Y
Transplantation; 2009 Aug; 88(3):303-7. PubMed ID: 19667930
[TBL] [Abstract][Full Text] [Related]
16. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute antibody-mediated rejection: a single-center experience.
Rodríguez Ferrero M; Rincón A; Bucalo L; Rementería A; Anaya F
Transplant Proc; 2010 Oct; 42(8):2848-50. PubMed ID: 20970547
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of acute humoral kidney allograft rejection.
Gomes AM; Pedroso S; Martins LS; Malheiro J; Viscayno JR; Santos J; Dias L; Henriques AC; Sarmento AM; Cabrita A
Transplant Proc; 2009 Apr; 41(3):855-8. PubMed ID: 19376371
[TBL] [Abstract][Full Text] [Related]
20. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
